Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) have received an average recommendation of “Moderate Buy” from the eighteen ratings firms that are currently covering the stock, Marketbeat reports. Six investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $48.71.

Several brokerages have issued reports on NTLA. Chardan Capital lifted their price target on shares of Intellia Therapeutics from $88.00 to $91.00 and gave the company a “buy” rating in a research note on Monday, November 18th. Wells Fargo & Company reduced their target price on shares of Intellia Therapeutics from $70.00 to $60.00 and set an “overweight” rating for the company in a report on Friday, January 10th. The Goldman Sachs Group reduced their target price on shares of Intellia Therapeutics from $19.00 to $12.00 and set a “neutral” rating for the company in a report on Tuesday, January 14th. Oppenheimer cut their price objective on shares of Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating for the company in a report on Monday, January 13th. Finally, William Blair reissued a “neutral” rating and issued a $14.00 price objective on shares of Intellia Therapeutics in a report on Monday, November 18th.

Intellia Therapeutics Trading Down 0.7 %

Shares of NTLA stock opened at $12.17 on Monday. Intellia Therapeutics has a 1 year low of $8.96 and a 1 year high of $34.87. The firm’s fifty day moving average price is $11.03 and its two-hundred day moving average price is $15.94. The firm has a market capitalization of $1.24 billion, a P/E ratio of -2.24 and a beta of 1.80.

Insider Activity

In related news, CEO John M. Leonard sold 26,807 shares of the stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total value of $326,509.26. Following the completion of the transaction, the chief executive officer now owns 941,115 shares of the company’s stock, valued at $11,462,780.70. This represents a 2.77 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last ninety days, insiders sold 29,000 shares of company stock worth $352,551. 3.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Intellia Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. bought a new position in Intellia Therapeutics in the 4th quarter valued at approximately $25,000. Sterling Capital Management LLC lifted its stake in Intellia Therapeutics by 866.2% in the 4th quarter. Sterling Capital Management LLC now owns 3,198 shares of the company’s stock valued at $37,000 after purchasing an additional 2,867 shares during the last quarter. Whipplewood Advisors LLC bought a new position in Intellia Therapeutics in the 4th quarter valued at approximately $40,000. Eastern Bank bought a new position in Intellia Therapeutics in the 3rd quarter valued at approximately $41,000. Finally, Resona Asset Management Co. Ltd. bought a new position in Intellia Therapeutics in the 4th quarter valued at approximately $43,000. Institutional investors own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.